• Mashup Score: 0
    Men's Breakfast and Health Screening (Prostate Screening) PSA - 1 year(s) ago

    Mark your calendar for Saturday, September 16th, 2023, from 9 am to 12 pm. Join us at New Covenant Church of Philadelphia for an enlightening Men’s Prostate Cancer information session and screening. Esteemed guests from Sidney Kimmel Cancer Center of Jefferson Health, including Dr. James Posey – Medical Oncologist, Josh Blanding-Godbolt – Clinical Research Coordinator, and Latese Evens MS – PhD…

    Source: nccop.churchcenter.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of KimmelCancerCtr
      KimmelCancerCtr

      Join SKCC experts on Sept. 16 @nccop_ for breakfast and an information session on #ProstateCancer research & prevention. Free PSA screenings will be available! 🔗 Register here: https://t.co/knhZdWvVq5 #ProstateCancerAwarenessMonth https://t.co/6vw9U6KwmP

  • Mashup Score: 0
    Dr. Scott Eggener Discusses Grade Group 1 Prostate Cancer - 1 year(s) ago

    Scott Eggener, MD, of UChicago Medicine, provides an overview of advancements in and patient perspectives on Grade Group 1 prostate cancer and discusses the minimization of unnecessary treatment by promoting active surveillance. Patients with prostate cancer were found to be overtreated for their low-risk disease, and so the Gleason scoring system was relabeled as the Grade Group scoring system. Active surveillance is co nsidered the preferred management approach in most guidelines for Grade Group 1

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      When should patients with Grade Group 1 #prostatecancer be biopsied? If an elevated risk of GG2 or higher cancer is found, this may ultimately cause problems for patients in the future. Watch our full interview with @uroegg: https://t.co/2nSS3xAJhb #ProstateCancerAwarenessMonth https://t.co/B9jPMzdyJw

  • Mashup Score: 0
    Dr. Scott Eggener Discusses Grade Group 1 Prostate Cancer - 1 year(s) ago

    Scott Eggener, MD, of UChicago Medicine, provides an overview of advancements in and patient perspectives on Grade Group 1 prostate cancer and discusses the minimization of unnecessary treatment by promoting active surveillance. Patients with prostate cancer were found to be overtreated for their low-risk disease, and so the Gleason scoring system was relabeled as the Grade Group scoring system. Active surveillance is co nsidered the preferred management approach in most guidelines for Grade Group 1

    Source: guoncologynow.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of GUOncologyNow
      GUOncologyNow

      What should patients know about Grade Group 1 #prostatecancer? @uroegg explains how overwhelming evidence shows that GG1 prostate cancer is not capable of spreading to other areas of the body: https://t.co/2nSS3xAJhb #ProstateCancerAwarenessMonth https://t.co/4EuqVz1QCx

  • Mashup Score: 1
    Mobile health checks could speed up diagnosis of prostate cancer - 2 year(s) ago

    Data from a pilot study suggest​the ‘Man Van’, an innovative targeted outreach programme, could improve healthcare access for men and potentially speed up the detection of prostate cancer.

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      🚚 The #ManVan is a mobile clinic that aims to improve healthcare access for men. With data showing it could speed up #ProstateCancer diagnosis, the programme has been awarded over £500k in funding from @NHSEngland ⬇️ https://t.co/0bBvDFJKeS #ProstateCancerAwarenessMonth https://t.co/CwsimDIRke

  • Mashup Score: 1
    Over a decade of abiraterone: the drug that revolutionised advanced prostate cancer care - 2 year(s) ago

    This Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer. We share the story of the drug’s discovery, how a landmark trial changed the way advanced prostate cancer is treated today, and what the drug has meant for patients who are currently treated with it.

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      Abiraterone has helped to extend the lives of thousands of men like Alfred, Rob and Tony around the world. Read more about the discovery and development of abiraterone below (5/5). #ProstateCancerAwarenessMonth https://t.co/gkQTZ2MCa4

  • Mashup Score: 0
    Over a decade of abiraterone: the drug that revolutionised advanced prostate cancer care - 2 year(s) ago

    This Prostate Cancer Awareness Month, we’re celebrating over 10 years since abiraterone was first recommended by NICE in England as a treatment for advanced prostate cancer. We share the story of the drug’s discovery, how a landmark trial changed the way advanced prostate cancer is treated today, and what the drug has meant for patients who are currently treated with it.

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      💊 Discovered by ICR scientists around 30 years ago, abiraterone has been available on the NHS for over a decade. This #ProstateCancerAwarenessMonth, we're looking back at how this drug became one of our greatest success stories⬇️ https://t.co/gkQTZ2MCa4 https://t.co/38a6y1DbKf

Load More